KEGG   Homo sapiens (human): 3784
Entry
3784              CDS       T01001                                 
Symbol
KCNQ1, ATFB1, ATFB3, JLNS1, KCNA8, KCNA9, KVLQT1, Kv1.9, Kv7.1, LQT, LQT1, RWS, SQT2, WRS
Name
(RefSeq) potassium voltage-gated channel subfamily Q member 1
  KO
K04926  potassium voltage-gated channel KQT-like subfamily member 1
Organism
hsa  Homo sapiens (human)
Pathway
hsa04261  Adrenergic signaling in cardiomyocytes
hsa04725  Cholinergic synapse
hsa04971  Gastric acid secretion
hsa04972  Pancreatic secretion
hsa04974  Protein digestion and absorption
hsa05110  Vibrio cholerae infection
Disease
H00713  Beckwith-Wiedemann syndrome
H00720  Long QT syndrome
H00725  Short QT syndrome
H00731  Atrial fibrillation
H02091  Jervell and Lange-Nielsen syndrome
Drug target
Ambasilide: D09758
Amiodarone (DG00204): D00636<JP/US> D02910
Azimilide dihydrochloride: D03037
Bepridil (DG00333): D00631<JP> D07520
Dronedarone (DG00207): D02537 D03914<US>
Flindokalner: D04192
Retigabine: D09569
Terikalant: D09757
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09150 Organismal Systems
  09153 Circulatory system
   04261 Adrenergic signaling in cardiomyocytes
    3784 (KCNQ1)
  09154 Digestive system
   04971 Gastric acid secretion
    3784 (KCNQ1)
   04972 Pancreatic secretion
    3784 (KCNQ1)
   04974 Protein digestion and absorption
    3784 (KCNQ1)
  09156 Nervous system
   04725 Cholinergic synapse
    3784 (KCNQ1)
 09160 Human Diseases
  09171 Infectious disease: bacterial
   05110 Vibrio cholerae infection
    3784 (KCNQ1)
 09180 Brite Hierarchies
  09183 Protein families: signaling and cellular processes
   04040 Ion channels [BR:hsa04040]
    3784 (KCNQ1)
Ion channels [BR:hsa04040]
 Voltage-gated cation channels
  Potassium channel, voltage-gated (Kv)
   3784 (KCNQ1)
SSDB
Motif
Pfam: Ion_trans KCNQ_channel Ion_trans_2 WDCP
Other DBs
NCBI-GeneID: 3784
NCBI-ProteinID: NP_000209
OMIM: 607542
HGNC: 6294
Ensembl: ENSG00000053918
UniProt: P51787 Q96AI9
Structure
LinkDB
Position
11:2445008..2849105
AA seq 676 aa
MAAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIAPGAPG
PAPPASPAAPAAPPVASDLGPRPPVSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGW
KCFVYHFAVFLIVLVCLIFSVLSTIEQYAALATGTLFWMEIVLVVFFGTEYVVRLWSAGC
RSKYVGLWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRMLH
VDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYA
DALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVFAISFFALPAGILGSGFALKVQQKQR
QKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYIRKAPRSHTLLSPSPKPKKSVVVKK
KKFKLDKDNGVTPGEKMLTVPHITCDPPEERRLDHFSVDGYDSSVRKSPTLLEVSMPHFM
RTNSFAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRD
VIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFISVSEKSKDRGSNTIGARLNRVEDKVT
QLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHITQPCGSGGSVDPELFLPSNTLP
TYEQLTVPRRGPDEGS
NT seq 2031 nt   +upstreamnt  +downstreamnt
atggccgcggcctcctccccgcccagggccgagaggaagcgctggggttggggccgcctg
ccaggcgcccggcggggcagcgcgggcctggccaagaagtgccccttctcgctggagctg
gcggagggcggcccggcgggcggcgcgctctacgcgcccatcgcgcccggcgccccaggt
cccgcgccccctgcgtccccggccgcgcccgccgcgcccccagttgcctccgaccttggc
ccgcggccgccggtgagcctagacccgcgcgtctccatctacagcacgcgccgcccggtg
ttggcgcgcacccacgtccagggccgcgtctacaacttcctcgagcgtcccaccggctgg
aaatgcttcgtttaccacttcgccgtcttcctcatcgtcctggtctgcctcatcttcagc
gtgctgtccaccatcgagcagtatgccgccctggccacggggactctcttctggatggag
atcgtgctggtggtgttcttcgggacggagtacgtggtccgcctctggtccgccggctgc
cgcagcaagtacgtgggcctctgggggcggctgcgctttgcccggaagcccatttccatc
atcgacctcatcgtggtcgtggcctccatggtggtcctctgcgtgggctccaaggggcag
gtgtttgccacgtcggccatcaggggcatccgcttcctgcagatcctgaggatgctacac
gtcgaccgccagggaggcacctggaggctcctgggctccgtggtcttcatccaccgccag
gagctgataaccaccctgtacatcggcttcctgggcctcatcttctcctcgtactttgtg
tacctggctgagaaggacgcggtgaacgagtcaggccgcgtggagttcggcagctacgca
gatgcgctgtggtggggggtggtcacagtcaccaccatcggctatggggacaaggtgccc
cagacgtgggtcgggaagaccatcgcctcctgcttctctgtctttgccatctccttcttt
gcgctcccagcggggattcttggctcggggtttgccctgaaggtgcagcagaagcagagg
cagaagcacttcaaccggcagatcccggcggcagcctcactcattcagaccgcatggagg
tgctatgctgccgagaaccccgactcctccacctggaagatctacatccggaaggccccc
cggagccacactctgctgtcacccagccccaaacccaagaagtctgtggtggtaaagaaa
aaaaagttcaagctggacaaagacaatggggtgactcctggagagaagatgctcacagtc
ccccatatcacgtgcgaccccccagaagagcggcggctggaccacttctctgtcgacggc
tatgacagttctgtaaggaagagcccaacactgctggaagtgagcatgccccatttcatg
agaaccaacagcttcgccgaggacctggacctggaaggggagactctgctgacacccatc
acccacatctcacagctgcgggaacaccatcgggccaccattaaggtcattcgacgcatg
cagtactttgtggccaagaagaaattccagcaagcgcggaagccttacgatgtgcgggac
gtcattgagcagtactcgcagggccacctcaacctcatggtgcgcatcaaggagctgcag
aggaggctggaccagtccattgggaagccctcactgttcatctccgtctcagaaaagagc
aaggatcgcggcagcaacacgatcggcgcccgcctgaaccgagtagaagacaaggtgacg
cagctggaccagaggctggcactcatcaccgacatgcttcaccagctgctctccttgcac
ggtggcagcacccccggcagcggcggcccccccagagagggcggggcccacatcacccag
ccctgcggcagtggcggctccgtcgaccctgagctcttcctgcccagcaacaccctgccc
acctacgagcagctgaccgtgcccaggaggggccccgatgaggggtcctga

KEGG   Homo sapiens (human): 9992
Entry
9992              CDS       T01001                                 
Symbol
KCNE2, ATFB4, LQT5, LQT6, MIRP1
Name
(RefSeq) potassium voltage-gated channel subfamily E regulatory subunit 2
  KO
K04896  potassium voltage-gated channel Isk-related subfamily E member 2
Organism
hsa  Homo sapiens (human)
Pathway
hsa04971  Gastric acid secretion
Disease
H00720  Long QT syndrome
H00731  Atrial fibrillation
Brite
KEGG Orthology (KO) [BR:hsa00001]
 09150 Organismal Systems
  09154 Digestive system
   04971 Gastric acid secretion
    9992 (KCNE2)
 09180 Brite Hierarchies
  09183 Protein families: signaling and cellular processes
   04040 Ion channels [BR:hsa04040]
    9992 (KCNE2)
Ion channels [BR:hsa04040]
 Voltage-gated cation channels
  Potassium channel, voltage-gated (Kv)
   9992 (KCNE2)
SSDB
Motif
Pfam: ISK_Channel SLC52_ribofla_tr SID-1_RNA_chan
Other DBs
NCBI-GeneID: 9992
NCBI-ProteinID: NP_751951
OMIM: 603796
HGNC: 6242
Ensembl: ENSG00000159197
UniProt: Q9Y6J6
Structure
LinkDB
Position
21:34364006..34371381
AA seq 123 aa
MSTLSNFTQTLEDVFRRIFITYMDNWRQNTTAEQEALQAKVDAENFYYVILYLMVMIGMF
SFIIVAILVSTVKSKRREHSNDPYHQYIVEDWQEKYKSQILNLEESKATIHENIGAAGFK
MSP
NT seq 372 nt   +upstreamnt  +downstreamnt
atgtctactttatccaatttcacacagacgctggaagacgtcttccgaaggatttttatt
acttatatggacaattggcgccagaacacaacagctgagcaagaggccctccaagccaaa
gttgatgctgagaacttctactatgtcatcctgtacctcatggtgatgattggaatgttc
tctttcatcatcgtggccatcctggtgagcactgtgaaatccaagagacgggaacactcc
aatgacccctaccaccagtacattgtagaggactggcaggaaaagtacaagagccaaatc
ttgaatctagaagaatcgaaggccaccatccatgagaacattggtgcggctgggttcaaa
atgtccccctga

KEGG   DISEASE: Beckwith-Wiedemann syndrome
Entry
H00713                      Disease                                
Name
Beckwith-Wiedemann syndrome
Description
Beckwith-Wiedemann syndrome (BWS) is an imprinting disorder characterized by overgrowth, tumor predisposition, and congenital malformations. It is associated with genetic or epigenetic abnormalities in a cluster of imprinted genes found within a genomic region of approximately one megabase on chromosome 11p15. The imprinted region 11p15 is separated into two domains, with each domain regulated by a functionally independent imprinting control regions (ICR). The centromeric ICR2 regulates the expression of CDKN1C, KCNQ1, and further genes. The majority of cases of BWS show hypomethylation in the ICR2 or mutations in the ICR2-regulated CDKN1C gene. In intron 10 of the KCNQ1 locus, the untranslated KCNQ1OT1 RNA is encoded. KCNQ10T1 is expressed by the paternal allele and probably represses realization of the CDKN1C gene. In the telomeric ICR1, hypermethylation of the H19 promoter and loss of imprinting of IGF2 have been reported in a small fraction of patients with BWS. A few BWS cases could be related to NSD1 deletions or mutations.
Category
Congenital malformation
Brite
Human diseases in ICD-11 classification [BR:br08403]
 20 Developmental anomalies
  Multiple developmental anomalies or syndromes
   LD2C  Overgrowth syndromes
    H00713  Beckwith-Wiedemann syndrome
Gene
CDKN1C [HSA:1028] [KO:K09993]
IGF2 [HSA:3481] [KO:K13769]
KCNQ1 [HSA:3784] [KO:K04926]
Comment
BWS and the growth retardation disorder Russell-Silver syndrome [DS:H00713] present two genetically and clinically opposite clinical pictures.
Other DBs
ICD-11: LD2C
MeSH: D001506
OMIM: 130650
Reference
  Authors
Choufani S, Shuman C, Weksberg R
  Title
Beckwith-Wiedemann syndrome.
  Journal
Am J Med Genet C Semin Med Genet 154C:343-54 (2010)
DOI:10.1002/ajmg.c.30267
Reference
  Authors
Weksberg R, Smith AC, Squire J, Sadowski P
  Title
Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development.
  Journal
Hum Mol Genet 12 Spec No 1:R61-8 (2003)
DOI:10.1093/hmg/ddg067
Reference
  Authors
Eggermann T
  Title
Silver-Russell and Beckwith-Wiedemann syndromes: opposite (epi)mutations in 11p15 result in opposite clinical pictures.
  Journal
Horm Res 71 Suppl 2:30-5 (2009)
DOI:10.1159/000192433
Reference
  Authors
Nativio R, Sparago A, Ito Y, Weksberg R, Riccio A, Murrell A
  Title
Disruption of genomic neighbourhood at the imprinted IGF2-H19 locus in Beckwith-Wiedemann syndrome and Silver-Russell syndrome.
  Journal
Hum Mol Genet 20:1363-74 (2011)
DOI:10.1093/hmg/ddr018
Reference
  Authors
Baujat G, Rio M, Rossignol S, Sanlaville D, Lyonnet S, Le Merrer M, Munnich A, Gicquel C, Cormier-Daire V, Colleaux L
  Title
Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome.
  Journal
Am J Hum Genet 74:715-20 (2004)
DOI:10.1086/383093
LinkDB

» Japanese version

KEGG   DISEASE: Long QT syndrome
Entry
H00720                      Disease                                
Name
Long QT syndrome
  Subgroup
Romano-Ward syndrome
Jervell and Lange-Nielsen syndrome (JLNS) [DS:H02091]
Timothy syndrome
Description
Long QT syndrome (LQTS) is a cardiovascular disorder resulting from mutations in cardiac ion channels. LQTS is characterized by prolongation of the QT interval in the electrocardiogram (ECG) and a propensity to torsades de pointes ventricular tachycardia frequently leading to syncope, cardiac arrest, or sudden death usually in young otherwise healthy individuals. Anesthesia in a patient with LQTS can trigger malignant arrhythmias and is therefore a high-risk procedure. There are two well-known syndromes with a long QT interval. The Romano-Ward syndrome is characterized by an autosomal-dominant inheritance without familial deafness. The Jervell and Lange-Nielsen syndrome (JLNS) has an autosomal-recessive pattern of inheritance and is associated with deafness.
Category
Cardiovascular disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 11 Diseases of the circulatory system
  Cardiac arrhythmia
   BC65  Cardiac arrhythmia associated with genetic disorder
    H00720  Long QT syndrome
Pathway-based classification of diseases [BR:br08402]
 Signal transduction
  nt06528  Calcium signaling
   H00720  Long QT syndrome
Pathway
hsa04020  Calcium signaling pathway
Network
nt06528 Calcium signaling
Gene
(LQT1) KCNQ1 [HSA:3784] [KO:K04926]
(LQT2) KCNH2 [HSA:3757] [KO:K04905]
(LQT3) SCN5A [HSA:6331] [KO:K04838]
(LQT4) ANK2 [HSA:287] [KO:K09255]
(LQT5) KCNE1 [HSA:3753] [KO:K04894]
(LQT6) KCNE2 [HSA:9992] [KO:K04896]
(LQT7) KCNJ2 [HSA:3759] [KO:K04996]
(LQT8) CACNA1C [HSA:775] [KO:K04850]
(LQT9) CAV3 [HSA:859] [KO:K12959]
(LQT10) SCN4B [HSA:6330] [KO:K04848]
(LQT11) AKAP9 [HSA:10142] [KO:K16551]
(LQT12) SNTA1 [HSA:6640] [KO:K24063]
(LQT13) KCNJ5 [HSA:3762] [KO:K04999]
(LQT14) CALM1 [HSA:801] [KO:K02183]
(LQT15) CALM2 [HSA:805] [KO:K02183]
(LQT16) CALM3 [HSA:808] [KO:K02183]
Other DBs
ICD-11: BC65.0
MeSH: D008133
OMIM: 192500 613688 603830 600919 613695 613693 170390 618447 601005 611818 611819 611820 612955 613485 616247 616249 618782
Reference
  Authors
Kim HT, Lee JH, Park IB, Heo HE, Kim TY, Lee MJ
  Title
Long QT syndrome provoked by induction of general anesthesia -A case report-.
  Journal
Korean J Anesthesiol 59 Suppl:S114-8 (2010)
DOI:10.4097/kjae.2010.59.S.S114
Reference
  Authors
Zareba W, Cygankiewicz I
  Title
Long QT syndrome and short QT syndrome.
  Journal
Prog Cardiovasc Dis 51:264-78 (2008)
DOI:10.1016/j.pcad.2008.10.006
Reference
  Authors
Saussine M, Massad I, Raczka F, Davy JM, Frapier JM
  Title
Torsade de pointes during sevoflurane anesthesia in a child with congenital long QT syndrome.
  Journal
Paediatr Anaesth 16:63-5 (2006)
DOI:10.1111/j.1460-9592.2005.01593.x
Reference
  Authors
Ilhan A, Tuncer C, Komsuoglu SS, Kali S
  Title
Jervell and Lange-Nielsen syndrome: neurologic and cardiologic evaluation.
  Journal
Pediatr Neurol 21:809-13 (1999)
DOI:10.1016/S0887-8994(99)00100-9
Reference
PMID:8528244 (LQT1)
  Authors
Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT
  Title
Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.
  Journal
Nat Genet 12:17-23 (1996)
DOI:10.1038/ng0196-17
Reference
PMID:7889573 (LQT2)
  Authors
Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT
  Title
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
  Journal
Cell 80:795-803 (1995)
DOI:10.1016/0092-8674(95)90358-5
Reference
PMID:8541846 (LQT3)
  Authors
Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT
  Title
Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia.
  Journal
Hum Mol Genet 4:1603-7 (1995)
DOI:10.1093/hmg/4.9.1603
Reference
PMID:12571597 (LQT4)
  Authors
Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V
  Title
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.
  Journal
Nature 421:634-9 (2003)
DOI:10.1038/nature01335
Reference
PMID:9354802 (LQT5)
  Authors
Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT
  Title
Mutations in the hminK gene cause long QT syndrome and suppress IKs function.
  Journal
Nat Genet 17:338-40 (1997)
DOI:10.1038/ng1197-338
Reference
PMID:10219239 (LQT6)
  Authors
Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA
  Title
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.
  Journal
Cell 97:175-87 (1999)
DOI:10.1016/S0092-8674(00)80728-X
Reference
PMID:11371347 (LQT7)
  Authors
Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL Jr, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptacek LJ
  Title
Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome.
  Journal
Cell 105:511-9 (2001)
DOI:10.1016/s0092-8674(01)00342-7
Reference
PMID:23677916 (LQT8)
  Authors
Boczek NJ, Best JM, Tester DJ, Giudicessi JR, Middha S, Evans JM, Kamp TJ, Ackerman MJ
  Title
Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome.
  Journal
Circ Cardiovasc Genet 6:279-89 (2013)
DOI:10.1161/CIRCGENETICS.113.000138
Reference
PMID:17060380 (LQT9)
  Authors
Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA
  Title
Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome.
  Journal
Circulation 114:2104-12 (2006)
DOI:10.1161/CIRCULATIONAHA.106.635268
Reference
PMID:17592081 (LQT10)
  Authors
Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusie-Luna MT, Makielski JC, Ackerman MJ
  Title
SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome.
  Journal
Circulation 116:134-42 (2007)
DOI:10.1161/CIRCULATIONAHA.106.659086
Reference
PMID:18093912 (LQT11)
  Authors
Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS
  Title
Mutation of an A-kinase-anchoring protein causes long-QT syndrome.
  Journal
Proc Natl Acad Sci U S A 104:20990-5 (2007)
DOI:10.1073/pnas.0710527105
Reference
PMID:18591664 (LQT12)
  Authors
Ueda K, Valdivia C, Medeiros-Domingo A, Tester DJ, Vatta M, Farrugia G, Ackerman MJ, Makielski JC
  Title
Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex.
  Journal
Proc Natl Acad Sci U S A 105:9355-60 (2008)
DOI:10.1073/pnas.0801294105
Reference
PMID:20560207 (LQT13)
  Authors
Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M, Olesen SP, Rasmussen HB, Ellinor PT, Gao L, Lin X, Li L, Wang L, Xiao J, Liu Y, Liu Y, Zhang S, Liang D, Peng L, Jespersen T, Chen YH
  Title
Identification of a Kir3.4 mutation in congenital long QT syndrome.
  Journal
Am J Hum Genet 86:872-80 (2010)
DOI:10.1016/j.ajhg.2010.04.017
Reference
PMID:23388215 (LQT14 LQT15)
  Authors
Crotti L, Johnson CN, Graf E, De Ferrari GM, Cuneo BF, Ovadia M, Papagiannis J, Feldkamp MD, Rathi SG, Kunic JD, Pedrazzini M, Wieland T, Lichtner P, Beckmann BM, Clark T, Shaffer C, Benson DW, Kaab S, Meitinger T, Strom TM, Chazin WJ, Schwartz PJ, George AL Jr
  Title
Calmodulin mutations associated with recurrent cardiac arrest in infants.
  Journal
Circulation 127:1009-17 (2013)
DOI:10.1161/CIRCULATIONAHA.112.001216
Reference
PMID:25460178 (LQT16)
  Authors
Reed GJ, Boczek NJ, Etheridge SP, Ackerman MJ
  Title
CALM3 mutation associated with long QT syndrome.
  Journal
Heart Rhythm 12:419-22 (2015)
DOI:10.1016/j.hrthm.2014.10.035
LinkDB

» Japanese version

KEGG   DISEASE: Short QT syndrome
Entry
H00725                      Disease                                
Name
Short QT syndrome
Description
Short QT syndrome (SQTS) is a cardiovascular disorder resulting from mutations in cardiac ion channels. The mutation of genes (KCNH2, KCNQ1, and KCNJ2) encoding for cardiac potassium channels plays a central role in SQTS. SQTS is characterized by constantly short QT interval associated with atrial fibrillation, syncopal episodes, and sudden cardiac death. The implantable cardioverter defibrillator (ICD) therapy in patients with a short QT syndrome has an increased risk due to possible T wave oversensing.
Category
Cardiovascular disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 11 Diseases of the circulatory system
  Cardiac arrhythmia
   BC65  Cardiac arrhythmia associated with genetic disorder
    H00725  Short QT syndrome
Gene
(SQT1) KCNH2 [HSA:3757] [KO:K04905]
(SQT2) KCNQ1 [HSA:3784] [KO:K04926]
(SQT3) KCNJ2 [HSA:3759] [KO:K04996]
(SQT7) SLC4A3 [HSA:6508] [KO:K13856]
Other DBs
ICD-11: BC65.2
MeSH: C566506 C566505 C566504
OMIM: 609620 609621 609622 620231
Reference
  Authors
Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M
  Title
Short QT syndrome.
  Journal
Cardiovasc Res 67:357-66 (2005)
DOI:10.1016/j.cardiores.2005.03.026
Reference
  Authors
Zareba W, Cygankiewicz I
  Title
Long QT syndrome and short QT syndrome.
  Journal
Prog Cardiovasc Dis 51:264-78 (2008)
DOI:10.1016/j.pcad.2008.10.006
Reference
  Authors
Crotti L, Taravelli E, Girardengo G, Schwartz PJ
  Title
Congenital short QT syndrome.
  Journal
Indian Pacing Electrophysiol J 10:86-95 (2010)
Reference
PMID:14676148 (SQT1)
  Authors
Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C
  Title
Sudden death associated with short-QT syndrome linked to mutations in HERG.
  Journal
Circulation 109:30-5 (2004)
DOI:10.1161/01.CIR.0000109482.92774.3A
Reference
PMID:15159330 (SQT2)
  Authors
Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, Baro I, Wilde AA
  Title
Mutation in the KCNQ1 gene leading to the short QT-interval syndrome.
  Journal
Circulation 109:2394-7 (2004)
DOI:10.1161/01.CIR.0000130409.72142.FE
Reference
PMID:15761194 (SQT3)
  Authors
Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A, Napolitano C, Anumonwo J, di Barletta MR, Gudapakkam S, Bosi G, Stramba-Badiale M, Jalife J
  Title
A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene.
  Journal
Circ Res 96:800-7 (2005)
DOI:10.1161/01.RES.0000162101.76263.8c
Reference
PMID:29167417 (SQT7)
  Authors
Thorsen K, Dam VS, Kjaer-Sorensen K, Pedersen LN, Skeberdis VA, Jurevicius J, Treinys R, Petersen IMBS, Nielsen MS, Oxvig C, Morth JP, Matchkov VV, Aalkjaer C, Bundgaard H, Jensen HK
  Title
Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome.
  Journal
Nat Commun 8:1696 (2017)
DOI:10.1038/s41467-017-01630-0
LinkDB

» Japanese version

KEGG   DISEASE: Atrial fibrillation
Entry
H00731                      Disease                                
Name
Atrial fibrillation
Description
Atrial fibrillation (AF, ATFB) is the most common cardiac arrhythmia and is regarded generally as a sporadic, acquired disorder. Nevertheless, recent growing evidence points to an important heritable basis for AF. By linkage analysis, several loci have been mapped for monogenetic AF. Some of these loci encode for subunits of potassium channels.
Category
Cardiovascular disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 11 Diseases of the circulatory system
  Cardiac arrhythmia
   Supraventricular rhythm disturbance
    BC81  Supraventricular tachyarrhythmia
     H00731  Atrial fibrillation
Pathway-based classification of diseases [BR:br08402]
 Cellular process
  nt06539  Cytoskeleton in muscle cells
   H00731  Atrial fibrillation
 Endocrine system
  nt06325  Hormone/cytokine signaling
   H00731  Atrial fibrillation
Pathway
hsa04261  Adrenergic signaling in cardiomyocytes
hsa04270  Vascular smooth muscle contraction
hsa04921  Oxytocin signaling pathway
hsa04725  Cholinergic synapse
hsa04924  Renin secretion
hsa04820  Cytoskeleton in muscle cells
Network
nt06325 Hormone/cytokine signaling
nt06539 Cytoskeleton in muscle cells
Gene
(ATFB3) KCNQ1 [HSA:3784] [KO:K04926]
(ATFB4) KCNE2 [HSA:9992] [KO:K04896]
(ATFB6) NPPA [HSA:4878] [KO:K12334]
(ATFB7) KCNA5 [HSA:3741] [KO:K04878]
(ATFB9) KCNJ2 [HSA:3759] [KO:K04996]
(ATFB10) SCN5A [HSA:6331] [KO:K04838]
(ATFB11) GJA5 [HSA:2702] [KO:K07614]
(ATFB12) ABCC9 [HSA:10060] [KO:K05033]
(ATFB13) SCN1B [HSA:6324] [KO:K04845]
(ATFB14) SCN2B [HSA:6327] [KO:K04846]
(ATFB15) NUP155 [HSA:9631] [KO:K14312]
(ATFB16/BRGDA7) SCN3B [HSA:55800] [KO:K04847]
(ATFB17/LQT10) SCN4B [HSA:6330] [KO:K04848]
(ATFB18) MYL4 [HSA:4635] [KO:K12750]
Drug
Quinidine sulfate [DR:D02272]
Flecainide acetate [DR:D00638]
Propranolol hydrochloride [DR:D00483]
Landiolol hydrochloride [DR:D01847]
Verapamil hydrochloride [DR:D00619]
Comment
ATFB16 and ATFB17 are also known as Brugada syndrome 7 (BRGDA7) [DS:H00728] and Long QT syndrome 10 (LQT10) [DS:H00720], respectively.
Other DBs
ICD-11: BC81.3
MeSH: D001281
OMIM: 608583 607554 611493 612201 612240 613980 614022 614049 614050 615377 615378 615770 617280
Reference
  Authors
Tsai CT, Lai LP, Hwang JJ, Lin JL, Chiang FT
  Title
Molecular genetics of atrial fibrillation.
  Journal
J Am Coll Cardiol 52:241-50 (2008)
DOI:10.1016/j.jacc.2008.02.072
Reference
  Authors
Otway R, Vandenberg JI, Fatkin D
  Title
Atrial fibrillation--a new cardiac channelopathy.
  Journal
Heart Lung Circ 16:356-60 (2007)
DOI:10.1016/j.hlc.2007.07.003
Reference
PMID:12522251 (ATFB3)
  Authors
Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W
  Title
KCNQ1 gain-of-function mutation in familial atrial fibrillation.
  Journal
Science 299:251-4 (2003)
DOI:10.1126/science.1077771
Reference
PMID:15368194 (ATFB4)
  Authors
Yang Y, Xia M, Jin Q, Bendahhou S, Shi J, Chen Y, Liang B, Lin J, Liu Y, Liu B, Zhou Q, Zhang D, Wang R, Ma N, Su X, Niu K, Pei Y, Xu W, Chen Z, Wan H, Cui J, Barhanin J, Chen Y
  Title
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation.
  Journal
Am J Hum Genet 75:899-905 (2004)
DOI:10.1086/425342
Reference
PMID:18614783 (ATFB6)
  Authors
Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, Ballew JD, de Andrade M, Burnett JC Jr, Olson TM
  Title
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation.
  Journal
N Engl J Med 359:158-65 (2008)
DOI:10.1056/NEJMoa0706300
Reference
PMID:16772329 (ATFB7)
  Authors
Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A
  Title
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation.
  Journal
Hum Mol Genet 15:2185-91 (2006)
DOI:10.1093/hmg/ddl143
Reference
PMID:15922306 (ATFB9)
  Authors
Xia M, Jin Q, Bendahhou S, He Y, Larroque MM, Chen Y, Zhou Q, Yang Y, Liu Y, Liu B, Zhu Q, Zhou Y, Lin J, Liang B, Li L, Dong X, Pan Z, Wang R, Wan H, Qiu W, Xu W, Eurlings P, Barhanin J, Chen Y
  Title
A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation.
  Journal
Biochem Biophys Res Commun 332:1012-9 (2005)
DOI:10.1016/j.bbrc.2005.05.054
Reference
PMID:16684018 (ATFB10)
  Authors
Laitinen-Forsblom PJ, Makynen P, Makynen H, Yli-Mayry S, Virtanen V, Kontula K, Aalto-Setala K
  Title
SCN5A mutation associated with cardiac conduction defect and atrial arrhythmias.
  Journal
J Cardiovasc Electrophysiol 17:480-5 (2006)
DOI:10.1111/j.1540-8167.2006.00411.x
Reference
PMID:16790700 (ATFB11)
  Authors
Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D
  Title
Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.
  Journal
N Engl J Med 354:2677-88 (2006)
DOI:10.1056/NEJMoa052800
Reference
PMID:17245405 (ATFB12)
  Authors
Olson TM, Alekseev AE, Moreau C, Liu XK, Zingman LV, Miki T, Seino S, Asirvatham SJ, Jahangir A, Terzic A
  Title
KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation.
  Journal
Nat Clin Pract Cardiovasc Med 4:110-6 (2007)
DOI:10.1038/ncpcardio0792
Reference
PMID:19808477 (ATFB13 ATFB14)
  Authors
Watanabe H, Darbar D, Kaiser DW, Jiramongkolchai K, Chopra S, Donahue BS, Kannankeril PJ, Roden DM
  Title
Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation.
  Journal
Circ Arrhythm Electrophysiol 2:268-75 (2009)
DOI:10.1161/CIRCEP.108.779181
Reference
PMID:19070573 (ATFB15)
  Authors
Zhang X, Chen S, Yoo S, Chakrabarti S, Zhang T, Ke T, Oberti C, Yong SL, Fang F, Li L, de la Fuente R, Wang L, Chen Q, Wang QK
  Title
Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death.
  Journal
Cell 135:1017-27 (2008)
DOI:10.1016/j.cell.2008.10.022
Reference
PMID:21051419 (ATFB16)
  Authors
Olesen MS, Jespersen T, Nielsen JB, Liang B, Moller DV, Hedley P, Christiansen M, Varro A, Olesen SP, Haunso S, Schmitt N, Svendsen JH
  Title
Mutations in sodium channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation.
  Journal
Cardiovasc Res 89:786-93 (2011)
DOI:10.1093/cvr/cvq348
Reference
PMID:23604097 (ATFB17)
  Authors
Li RG, Wang Q, Xu YJ, Zhang M, Qu XK, Liu X, Fang WY, Yang YQ
  Title
Mutations of the SCN4B-encoded sodium channel beta4 subunit in familial atrial fibrillation.
  Journal
Int J Mol Med 32:144-50 (2013)
DOI:10.3892/ijmm.2013.1355
Reference
PMID:27066836 (ATFB18)
  Authors
Orr N, Arnaout R, Gula LJ, Spears DA, Leong-Sit P, Li Q, Tarhuni W, Reischauer S, Chauhan VS, Borkovich M, Uppal S, Adler A, Coughlin SR, Stainier DY, Gollob MH
  Title
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation.
  Journal
Nat Commun 7:11303 (2016)
DOI:10.1038/ncomms11303
LinkDB

» Japanese version

KEGG   DISEASE: Jervell and Lange-Nielsen syndrome
Entry
H02091                      Disease                                
Name
Jervell and Lange-Nielsen syndrome
  Supergrp
Long QT syndrome [DS:H00720]
Description
Jervell Lange-Nielsen syndrome (JLNS) is a rare autosomal recessive disorder with congenital deafness and long-QT syndrome. Mutations in the potassium-channel gene KVLQT1 have been identified in JLNS. Recently, mutations in KCNE1 also have been found to cause JLNS.
Category
Cardiovascular disease
Brite
Human diseases in ICD-11 classification [BR:br08403]
 11 Diseases of the circulatory system
  Cardiac arrhythmia
   BC65  Cardiac arrhythmia associated with genetic disorder
    H02091  Jervell and Lange-Nielsen syndrome
Pathway
hsa04261  Adrenergic signaling in cardiomyocytes
Gene
(JLNS1) KCNQ1 [HSA:3784] [KO:K04926]
(JLNS2) KCNE1 [HSA:3753] [KO:K04894]
Other DBs
ICD-11: BC65.0
MeSH: D029593
OMIM: 220400 612347
Reference
  Authors
Chen Q, Zhang D, Gingell RL, Moss AJ, Napolitano C, Priori SG, Schwartz PJ, Kehoe E, Robinson JL, Schulze-Bahr E, Wang Q, Towbin JA
  Title
Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome.
  Journal
Circulation 99:1344-7 (1999)
DOI:10.1161/01.CIR.99.10.1344
Reference
PMID:9445165
  Authors
Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH
  Title
Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome.
  Journal
Circulation 97:142-6 (1998)
DOI:10.1161/01.CIR.97.2.142
Reference
PMID:9341873
  Authors
Schulze-Bahr E, Haverkamp W, Wedekind H, Rubie C, Hordt M, Borggrefe M, Assmann G, Breithardt G, Funke H
  Title
Autosomal recessive long-QT syndrome (Jervell Lange-Nielsen syndrome) is genetically heterogeneous.
  Journal
Hum Genet 100:573-6 (1997)
DOI:10.1007/s004390050554
LinkDB

» Japanese version

KEGG   DRUG: Bepridil hydrochloride
Entry
D00631                      Drug                                   
Name
Bepridil hydrochloride (USAN);
Bepridil hydrochloride hydrate (JAN);
Vascor (TN)
Formula
C24H34N2O. HCl. H2O
Exact mass
420.2544
Mol weight
421.01
Structure
Simcomp
Class
Cardiovascular agent
 DG01575  Calcium channel blocker
  DG01496  Calcium channel L type blocker
 DG01653  Antiarrhythmics
  DG01807  Phenylalkylamine derivative
Metabolizing enzyme substrate
 DG01642  CYP2C9 substrate
 DG01644  CYP2D6 substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01645  CYP2D6 inhibitor
Remark
Therapeutic category: 2129
ATC code: C08EA02
Chemical structure group: DG00333
Product (DG00333): D00631<JP>
Efficacy
Antiarrhythmic, Vasodilator (coronary), Calcium channel blocker, Sodium channel blocker, Potassium channel blocker
Target
CACNA1-L [HSA:775 776 778 779] [KO:K04850 K04851 K04853 K04857]
CACNA1-T [HSA:8911 8912 8913] [KO:K04856 K04855 K04854]
KCNH2 [HSA:3757] [KO:K04905]
KCNQ1 [HSA:3784] [KO:K04926]
KCNA5 [HSA:3741] [KO:K04878]
KCND3 [HSA:3752] [KO:K04893]
KCNJ3 [HSA:3760] [KO:K04997]
KCNJ5 [HSA:3762] [KO:K04999]
KCNJ8 [HSA:3764] [KO:K05001]
KCNJ11 [HSA:3767] [KO:K05004]
KCNJ12 [HSA:3768] [KO:K05005]
ATP1A [HSA:476 477 478 480] [KO:K01539]
  Pathway
hsa04010  MAPK signaling pathway
hsa04020  Calcium signaling pathway
hsa04022  cGMP-PKG signaling pathway
hsa04024  cAMP signaling pathway
hsa04260  Cardiac muscle contraction
hsa04270  Vascular smooth muscle contraction
Metabolism
Enzyme: CYP2D6 [HSA:1565], CYP2C9 [HSA:1559], CYP3A4 [HSA:1576]
Interaction
CYP inhibition: CYP2D6 [HSA:1565]
Structure map
map07036  Calcium channel blocking drugs
map07037  Antiarrhythmic drugs
map07231  Sodium channel blocking drugs
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C08 CALCIUM CHANNEL BLOCKERS
   C08E NON-SELECTIVE CALCIUM CHANNEL BLOCKERS
    C08EA Phenylalkylamine derivatives
     C08EA02 Bepridil
      D00631  Bepridil hydrochloride (USAN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   212  Antiarrhythmic agents
    2129  Others
     D00631  Bepridil hydrochloride (USAN); Bepridil hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01575  Calcium channel blocker
   DG01496  Calcium channel L type blocker
    DG00333  Bepridil
     D00631  Bepridil hydrochloride
  DG01653  Antiarrhythmics
   DG01807  Phenylalkylamine derivative
    DG00333  Bepridil
     D00631  Bepridil hydrochloride
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   DG00333  Bepridil
    D00631  Bepridil hydrochloride
  DG01644  CYP2D6 substrate
   DG00333  Bepridil
    D00631  Bepridil hydrochloride
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00333  Bepridil
     D00631  Bepridil hydrochloride
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG00333  Bepridil
    D00631  Bepridil hydrochloride
Drug classes [BR:br08332]
 Cardiovascular agent
  DG01653  Antiarrhythmics
   D00631  Bepridil hydrochloride
Target-based classification of drugs [BR:br08310]
 Ion channels
  Voltage-gated ion channels
   Calcium channels
    CACNA1-T
     D00631  Bepridil hydrochloride (USAN) <JP>
    CACNA1-L
     D00631  Bepridil hydrochloride (USAN) <JP>
   Potassium channels
    KCNA5
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCND3
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNH2
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNQ1
     D00631  Bepridil hydrochloride (USAN) <JP>
   Inward rectifier channels (Kir)
    KCNJ3
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNJ5
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNJ8
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNJ11
     D00631  Bepridil hydrochloride (USAN) <JP>
    KCNJ12
     D00631  Bepridil hydrochloride (USAN) <JP>
 Enzymes
  Hydrolases (EC3)
   ATPase
    ATP1A
     D00631  Bepridil hydrochloride (USAN) <JP>
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D00631
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01575  Calcium channel blocker
   DG01496  Calcium channel L type blocker
    DG00333  Bepridil
  DG01653  Antiarrhythmics
   DG01807  Phenylalkylamine derivative
    DG00333  Bepridil
 Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   DG00333  Bepridil
  DG01644  CYP2D6 substrate
   DG00333  Bepridil
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00333  Bepridil
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG00333  Bepridil
Other DBs
CAS: 74764-40-2
PubChem: 7847697
LigandBox: D00631
NIKKAJI: J395.749G
LinkDB
KCF data

ATOM        29
            1   N1c N    23.4624  -19.3400
            2   C1b C    24.6731  -20.0358
            3   C1b C    22.2518  -20.0418
            4   C1c C    25.8837  -19.3400
            5   C8y C    21.0411  -19.3400
            6   N1y N    27.1003  -20.0358
            7   C1b C    25.8837  -17.9363
            8   C8x C    19.8305  -20.0418
            9   C8x C    21.0411  -17.9421
            10  C1x C    28.2348  -19.2112
            11  C1x C    27.5330  -21.3693
            12  O2a O    27.0944  -17.2402
            13  C8x C    18.6141  -19.3400
            14  C8x C    19.8305  -17.2402
            15  C1x C    29.3695  -20.0358
            16  C1x C    28.9309  -21.3693
            17  C1b C    28.3108  -17.9363
            18  C8x C    18.6141  -17.9421
            19  C1c C    29.5214  -17.2345
            20  C1a C    30.7321  -17.9363
            21  C1a C    29.5214  -15.8367
            22  C8y C    23.4599  -17.9200
            23  C8x C    24.6637  -17.2222
            24  C8x C    24.6612  -15.8222
            25  C8x C    23.4475  -15.1243
            26  C8x C    22.2437  -15.8222
            27  C8x C    22.2462  -17.2222
            28  O0  O    36.0999  -19.7939
            29  X   Cl   33.2761  -19.7939
BOND        29
            1     1   2 1
            2     1   3 1
            3     2   4 1
            4     3   5 1
            5     4   6 1
            6     4   7 1
            7     5   8 2
            8     5   9 1
            9     6  10 1
            10    6  11 1
            11    7  12 1
            12    8  13 1
            13    9  14 2
            14   10  15 1
            15   11  16 1
            16   12  17 1
            17   13  18 2
            18   17  19 1
            19   19  20 1
            20   19  21 1
            21   14  18 1
            22   15  16 1
            23    1  22 1
            24   22  23 2
            25   23  24 1
            26   24  25 2
            27   25  26 1
            28   26  27 2
            29   22  27 1

» Japanese version   » Back

KEGG   DRUG: Amiodarone hydrochloride
Entry
D00636                      Drug                                   
Name
Amiodarone hydrochloride (JP18/USP);
Ancaron (TN);
Cordarone (TN);
Nexterone (TN)
Product
  Generic
AMIODARONE HCI (HF Acquisition Co LLC), AMIODARONE HYDROCHLORIDE (A-S Medication Solutions), AMIODARONE HYDROCHLORIDE (A-S Medication Solutions), AMIODARONE HYDROCHLORIDE (Advagen Pharma Limited), AMIODARONE HYDROCHLORIDE (American Health Packaging), AMIODARONE HYDROCHLORIDE (AuroMedics Pharma LLC), AMIODARONE HYDROCHLORIDE (Aurobindo Pharma Limited), AMIODARONE HYDROCHLORIDE (AvKARE), AMIODARONE HYDROCHLORIDE (AvPAK), AMIODARONE HYDROCHLORIDE (Bryant Ranch Prepack), AMIODARONE HYDROCHLORIDE (Bryant Ranch Prepack), AMIODARONE HYDROCHLORIDE (Bryant Ranch Prepack), AMIODARONE HYDROCHLORIDE (Cardinal Health 107), AMIODARONE HYDROCHLORIDE (Cardinal Health 107), AMIODARONE HYDROCHLORIDE (Chartwell RX), AMIODARONE HYDROCHLORIDE (Dr. Reddy's Labratories), AMIODARONE HYDROCHLORIDE (Fresenius Kabi USA), AMIODARONE HYDROCHLORIDE (Fresenius Kabi USA), AMIODARONE HYDROCHLORIDE (Gland Pharma Limited), AMIODARONE HYDROCHLORIDE (Golden State Medical Supply), AMIODARONE HYDROCHLORIDE (HF Acquisition Co LLC), AMIODARONE HYDROCHLORIDE (HF Acquisition Co LLC), AMIODARONE HYDROCHLORIDE (Hainan Poly Pharm.), AMIODARONE HYDROCHLORIDE (Henry Schein), AMIODARONE HYDROCHLORIDE (Hikma Pharmaceuticals USA), AMIODARONE HYDROCHLORIDE (Major Pharmaceuticals), AMIODARONE HYDROCHLORIDE (Mayne Pharma Commercial LLC), AMIODARONE HYDROCHLORIDE (McKesson Corporation dba SKY Packaging), AMIODARONE HYDROCHLORIDE (Medical Purchasing Solutions), AMIODARONE HYDROCHLORIDE (Medical Purchasing Solutions), AMIODARONE HYDROCHLORIDE (Medical Purchasing Solutions), AMIODARONE HYDROCHLORIDE (Medical Purchasing Solutions), AMIODARONE HYDROCHLORIDE (Mylan Institutional LLC), AMIODARONE HYDROCHLORIDE (Mylan Institutional LLC), AMIODARONE HYDROCHLORIDE (NCS HealthCare of KY), AMIODARONE HYDROCHLORIDE (NCS HealthCare of KY), AMIODARONE HYDROCHLORIDE (ProPharma Distribution), AMIODARONE HYDROCHLORIDE (REMEDYREPACK), AMIODARONE HYDROCHLORIDE (REMEDYREPACK), AMIODARONE HYDROCHLORIDE (REMEDYREPACK), AMIODARONE HYDROCHLORIDE (Slate Run Pharmaceuticals), AMIODARONE HYDROCHLORIDE (Sun Pharmaceutical Industries), AMIODARONE HYDROCHLORIDE (Unichem Pharmaceuticals (USA)), AMIODARONE HYDROCHLORIDE (Zhejiang Poly Pharm.), AMIODARONE HYDROCHLORIDE (Zydus Lifesciences Limited), AMIODARONE HYDROCHLORIDE (Zydus Pharmaceuticals USA), PACERONE (Aphena Pharma Solutions - Tennessee), PACERONE (Bryant Ranch Prepack), PACERONE (Upsher-Smith Laboratories)
Formula
C25H29I2NO3. HCl
Exact mass
681.0004
Mol weight
681.77
Structure
Simcomp
Class
Cardiovascular agent
 DG01456  Adrenergic receptor agonist
  DG01455  beta-Adrenergic receptor agonist
   DG01451  beta1-Adrenergic receptor agonist
 DG01653  Antiarrhythmics
  DG01648  Class III antiarrhythmic agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 2129
ATC code: C01BD01
Chemical structure group: DG00204
Product (DG00204): D00636<JP/US>
Efficacy
Antiarrhythmic, Potassium channel blocker
Target
KCND3 [HSA:3752] [KO:K04893]
KCNH2 [HSA:3757] [KO:K04905]
KCNQ1 [HSA:3784] [KO:K04926]
KCNJ3 [HSA:3760] [KO:K04997]
KCNJ5 [HSA:3762] [KO:K04999]
KCNJ8 [HSA:3764] [KO:K05001]
KCNJ11 [HSA:3767] [KO:K05004]
KCNJ12 [HSA:3768] [KO:K05005]
ADRA1 [HSA:148 147 146] [KO:K04135 K04136 K04137]
ADRB1 [HSA:153] [KO:K04141]
SCN1A [HSA:6323] [KO:K04833]
SCN2A [HSA:6326] [KO:K04834]
SCN3A [HSA:6328] [KO:K04836]
SCN4A [HSA:6329] [KO:K04837]
SCN5A [HSA:6331] [KO:K04838]
SCN8A [HSA:6334] [KO:K04840]
SCN9A [HSA:6335] [KO:K04841]
SCN10A [HSA:6336] [KO:K04842]
SCN11A [HSA:11280] [KO:K04843]
  Pathway
hsa04020  Calcium signaling pathway
hsa04022  cGMP-PKG signaling pathway
hsa04024  cAMP signaling pathway
hsa04080  Neuroactive ligand-receptor interaction
hsa04261  Adrenergic signaling in cardiomyocytes
hsa04270  Vascular smooth muscle contraction
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Structure map
map07037  Antiarrhythmic drugs
map07231  Sodium channel blocking drugs
map07232  Potassium channel blocking and opening drugs
Other map
map05320  Autoimmune thyroid disease
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C01 CARDIAC THERAPY
   C01B ANTIARRHYTHMICS, CLASS I AND III
    C01BD Antiarrhythmics, class III
     C01BD01 Amiodarone
      D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Antiarrhythmics
   Vaughn Williams-Class III
    Amiodarone
     D00636  Amiodarone hydrochloride (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   212  Antiarrhythmic agents
    2129  Others
     D00636  Amiodarone hydrochloride (JP18/USP)
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01456  Adrenergic receptor agonist
   DG01455  beta-Adrenergic receptor agonist
    DG01451  beta1-Adrenergic receptor agonist
     DG00204  Amiodarone
      D00636  Amiodarone hydrochloride
  DG01653  Antiarrhythmics
   DG01648  Class III antiarrhythmic agent
    DG00204  Amiodarone
     D00636  Amiodarone hydrochloride
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00204  Amiodarone
     D00636  Amiodarone hydrochloride
Drug classes [BR:br08332]
 Cardiovascular agent
  DG01653  Antiarrhythmics
   D00636  Amiodarone hydrochloride
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Rhodopsin family
   Adrenaline
    ADRA1
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    ADRB1
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
 Ion channels
  Voltage-gated ion channels
   Sodium channels
    SCN1A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN2A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN3A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN4A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN5A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN8A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN9A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN10A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    SCN11A
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
   Potassium channels
    KCND3
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNH2
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNQ1
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
   Inward rectifier channels (Kir)
    KCNJ3
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNJ5
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNJ8
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNJ11
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
    KCNJ12
     D00636  Amiodarone hydrochloride (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D00636  Amiodarone hydrochloride
  D00636  Amiodarone hydrochloride tablets
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D00636
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01456  Adrenergic receptor agonist
   DG01455  beta-Adrenergic receptor agonist
    DG01451  beta1-Adrenergic receptor agonist
     DG00204  Amiodarone
  DG01653  Antiarrhythmics
   DG01648  Class III antiarrhythmic agent
    DG00204  Amiodarone
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG00204  Amiodarone
Other DBs
CAS: 19774-82-4
PubChem: 7847702
LigandBox: D00636
NIKKAJI: J231.357J
LinkDB
KCF data

ATOM        32
            1   X   Cl   30.8700  -29.7500
            2   C8x C    16.7300  -27.2300
            3   C8x C    16.7300  -28.6300
            4   C8x C    17.9424  -29.3300
            5   C8y C    19.1549  -28.6300
            6   C8y C    19.1549  -27.2300
            7   C8x C    17.9424  -26.5300
            8   O2x O    20.4864  -29.0626
            9   C8y C    21.3093  -27.9300
            10  C8y C    20.4864  -26.7974
            11  C5a C    20.4864  -25.3974
            12  C8y C    21.7108  -24.6902
            13  O5a O    19.2971  -24.7108
            14  C8x C    22.9237  -25.3902
            15  C8y C    24.1360  -24.6900
            16  C8y C    24.1357  -23.2900
            17  C8y C    22.9229  -22.5900
            18  C8x C    21.7105  -23.2902
            19  O2a O    25.3499  -22.5887
            20  X   I    25.3678  -25.4007
            21  X   I    22.9222  -21.2104
            22  C1b C    26.5641  -23.2894
            23  C1b C    27.7419  -22.6091
            24  N1c N    28.9383  -23.2997
            25  C1b C    30.1249  -22.6143
            26  C1b C    28.9387  -24.7097
            27  C1a C    30.1297  -25.3972
            28  C1a C    31.3168  -23.3024
            29  C1b C    22.6800  -27.9300
            30  C1b C    23.3800  -29.1424
            31  C1b C    24.7798  -29.1424
            32  C1a C    25.4703  -30.3380
BOND        33
            1     2   3 2
            2     3   4 1
            3     4   5 2
            4     5   6 1
            5     6   7 2
            6     2   7 1
            7     5   8 1
            8     8   9 1
            9     9  10 2
            10    6  10 1
            11   10  11 1
            12   11  12 1
            13   11  13 2
            14   12  14 2
            15   14  15 1
            16   15  16 2
            17   16  17 1
            18   17  18 2
            19   12  18 1
            20   16  19 1
            21   15  20 1
            22   17  21 1
            23   19  22 1
            24   22  23 1
            25   23  24 1
            26   24  25 1
            27   24  26 1
            28   26  27 1
            29   25  28 1
            30    9  29 1
            31   29  30 1
            32   30  31 1
            33   31  32 1

» Japanese version   » Back

KEGG   DRUG: Dronedarone
Entry
D02537                      Drug                                   
Name
Dronedarone (INN)
Formula
C31H44N2O5S
Exact mass
556.2971
Mol weight
556.76
Structure
Simcomp
Class
Cardiovascular agent
 DG01575  Calcium channel blocker
  DG01496  Calcium channel L type blocker
 DG01456  Adrenergic receptor agonist
 DG01653  Antiarrhythmics
  DG01648  Class III antiarrhythmic agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01645  CYP2D6 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
Transporter inhibitor
 DG01622  ABCB1 inhibitor
Remark
ATC code: C01BD07
Chemical structure group: DG00207
Product (DG00207): D03914<US>
Efficacy
Antiarrhythmic
Comment
Amiodarone derivative
Target
CACNA1-L [HSA:775 776 778 779] [KO:K04850 K04851 K04853 K04857]
KCND3 [HSA:3752] [KO:K04893]
KCNH2 [HSA:3757] [KO:K04905]
KCNQ1 [HSA:3784] [KO:K04926]
KCNJ3 [HSA:3760] [KO:K04997]
KCNJ5 [HSA:3762] [KO:K04999]
ADRA1 [HSA:148 147 146] [KO:K04135 K04136 K04137]
ADRB1 [HSA:153] [KO:K04141]
  Pathway
hsa04010  MAPK signaling pathway
hsa04020  Calcium signaling pathway
hsa04260  Cardiac muscle contraction
hsa04261  Adrenergic signaling in cardiomyocytes
hsa04270  Vascular smooth muscle contraction
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Interaction
CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
Transporter inhibition: ABCB1 [HSA:5243]
Structure map
map07037  Antiarrhythmic drugs
map07231  Sodium channel blocking drugs
map07232  Potassium channel blocking and opening drugs
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C01 CARDIAC THERAPY
   C01B ANTIARRHYTHMICS, CLASS I AND III
    C01BD Antiarrhythmics, class III
     C01BD07 Dronedarone
      D02537  Dronedarone (INN)
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01575  Calcium channel blocker
   DG01496  Calcium channel L type blocker
    DG00207  Dronedarone
     D02537  Dronedarone
  DG01456  Adrenergic receptor agonist
   DG00207  Dronedarone
    D02537  Dronedarone
  DG01653  Antiarrhythmics
   DG01648  Class III antiarrhythmic agent
    DG00207  Dronedarone
     D02537  Dronedarone
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG00207  Dronedarone
    D02537  Dronedarone
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG00207  Dronedarone
    D02537  Dronedarone
  DG02852  CYP3A/CYP3A4 inhibitor
   DG00207  Dronedarone
    D02537  Dronedarone
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   DG00207  Dronedarone
    D02537  Dronedarone
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Rhodopsin family
   Adrenaline
    ADRA1
     D02537  Dronedarone (INN)
    ADRB1
     D02537  Dronedarone (INN)
 Ion channels
  Voltage-gated ion channels
   Calcium channels
    CACNA1-L
     D02537  Dronedarone (INN)
   Potassium channels
    KCND3
     D02537  Dronedarone (INN)
    KCNH2
     D02537  Dronedarone (INN)
    KCNQ1
     D02537  Dronedarone (INN)
   Inward rectifier channels (Kir)
    KCNJ3
     D02537  Dronedarone (INN)
    KCNJ5
     D02537  Dronedarone (INN)
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D02537
 Drug transporters
  D02537
Drug groups [BR:br08330]
 Cardiovascular agent
  DG01575  Calcium channel blocker
   DG01496  Calcium channel L type blocker
    DG00207  Dronedarone
  DG01456  Adrenergic receptor agonist
   DG00207  Dronedarone
  DG01653  Antiarrhythmics
   DG01648  Class III antiarrhythmic agent
    DG00207  Dronedarone
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG00207  Dronedarone
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG00207  Dronedarone
  DG02852  CYP3A/CYP3A4 inhibitor
   DG00207  Dronedarone
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   DG00207  Dronedarone
Other DBs
CAS: 141626-36-0
PubChem: 17396708
LigandBox: D02537
NIKKAJI: J631.227F
LinkDB
KCF data

ATOM        39
            1   C8y C    22.8367  -17.7635
            2   C8x C    22.8367  -19.1718
            3   C8x C    24.0563  -19.8760
            4   C8y C    25.2760  -19.1718
            5   C8y C    25.2760  -17.7635
            6   C8x C    24.0563  -17.0594
            7   O2x O    26.6154  -19.6070
            8   C8y C    27.4432  -18.4677
            9   C8y C    26.6154  -17.3284
            10  N1b N    21.6172  -17.0594
            11  S4a S    20.4146  -17.7539
            12  C1a C    19.1949  -18.4580
            13  O3c O    21.1296  -18.9929
            14  O3c O    19.7219  -16.5537
            15  C5a C    26.6154  -15.9201
            16  C8y C    27.8471  -15.2087
            17  O5a O    25.4191  -15.2294
            18  C1b C    28.8220  -18.4677
            19  C8x C    29.0672  -15.9128
            20  C8x C    30.2867  -15.2085
            21  C8y C    30.2863  -13.8002
            22  C8x C    29.0664  -13.0960
            23  C8x C    27.8468  -13.8004
            24  O2a O    31.5077  -13.0947
            25  C1b C    32.7291  -13.7996
            26  C1b C    33.9139  -13.1152
            27  C1b C    35.1174  -13.8099
            28  N1c N    36.3111  -13.1205
            29  C1b C    37.5100  -13.8127
            30  C1b C    38.7060  -13.1219
            31  C1b C    29.5262  -17.2481
            32  C1b C    30.9343  -17.2481
            33  C1a C    31.6289  -16.0454
            34  C1b C    36.3110  -11.7080
            35  C1b C    37.5118  -11.0146
            36  C1b C    38.7052  -11.7034
            37  C1a C    39.9039  -11.0110
            38  C1b C    39.9037  -13.8134
            39  C1a C    41.1003  -13.1223
BOND        41
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 2
            10    5   9 1
            11    1  10 1
            12   10  11 1
            13   11  12 1
            14   11  13 2
            15   11  14 2
            16    9  15 1
            17   15  16 1
            18   15  17 2
            19    8  18 1
            20   16  19 2
            21   19  20 1
            22   20  21 2
            23   21  22 1
            24   22  23 2
            25   16  23 1
            26   21  24 1
            27   24  25 1
            28   25  26 1
            29   26  27 1
            30   27  28 1
            31   28  29 1
            32   29  30 1
            33   18  31 1
            34   31  32 1
            35   32  33 1
            36   28  34 1
            37   34  35 1
            38   35  36 1
            39   36  37 1
            40   30  38 1
            41   38  39 1

» Japanese version   » Back

DBGET integrated database retrieval system